전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,092 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleStemcentrxPhase 1

Rovalpituzumab Tesirine (Rovalpituzumab Tesirine)

Small Cell Lung Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase1#monoclonal-antibody#SmallCellLungCarcinoma+1
Trials 13Status Active
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

T cell infusion agent targeting BCMA chimeric antigen receptor (T cell infusion agent targeting BCMA chimeric antigen receptor)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 13Status Active
ADCLimited DatastaleAbbViePhase 2

Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)

Metastatic Colorectal Cancer · Non Small Cell Lung Carcinoma

#NonSmallCellLungCarcinoma#ADC#Phase2#antibody-drug-conjugate#MetastaticColorectalCancer+1
Trials 13Status Recruiting
AntibodyLimited DatastaleNational Cancer Centre, Singapo…Phase 2

atezolizumab (Tecentriq, Adjuvant Atezolizumab-Bevacizumab Therapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#National
Trials 12Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

Relapsed and/or Refractory Acute Myeloid Leukemia; High Risk Hematologic Malignancies · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 12Status Active
CGTLimited DatastaleBiohaven Pharmaceuticals, Inc.Phase 1

CIML-NK cell therapy (CIML-NK cell therapy)

Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 12Status Recruiting
CGTLimited DatastaleShenzhen Institute for Innovati…Phase 2

Drugs and anti-CD19 CAR transduced T cells (Drugs and anti-CD19 CAR transduced T cells)

Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 12Status Active
CGTLimited DatastaleVyriad, Inc.Phase 2

Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter (Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter)

Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Clear Cell Adenocarcinoma

#FallopianTubeClearCellAdenocarci#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 12Status Active
ADCLimited DatastaleRochePhase 2

Polatuzumab Vedotin, Rituximab, Lenalidomide (Polatuzumab Vedotin, Rituximab, Lenalidomide)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 12Status Recruiting
CGTLimited DatastaleHrain Biotechnology Co., Ltd.Phase 1

anti-MESO CAR-T cells (anti-MESO CAR-T cells)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 12Status Active
CGTLimited DatastaleXi'niao BiotechPhase 1

universal allogeneic anti-CD19/BCMA CAR T-cells (universal allogeneic anti-CD19/BCMA CAR T-cells)

Autoimmune Hemolytic Anemia; CD19/BCMA CAR T-cells · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 12Status Recruiting
ADCLimited DatastaleLepu Biopharma Co., Ltd.Phase 2

Becotatug Vedotin and Pucotenlimab (Becotatug Vedotin and Pucotenlimab)

Hypopharyngeal Squamous Cell Carcinoma · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#ADC#Phase2#antibody-drug-conjugate#HypopharyngealSquamousCellCarcin+1
Trials 11Status Recruiting
AntibodyLimited DatastaleShi MingPhase 2

Candonilimab (Candonilimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Shi
Trials 11Status Discontinued
CGTLimited DatastaleKyverna TherapeuticsPhase 2

KYV-101 anti-CD19 CAR-T cell therapy (KYV-101 anti-CD19 CAR-T cell therapy)

Lupus Nephritis; Lupus Nephritis - WHO Class III · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 11Status Discontinued
AntibodyLimited DatastaleLepu Medical Technology (Beijin…Phase 2

MRG003+Pucotenlimab (MRG003+Pucotenlimab)

Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma · Locally Advanced Oral and Oropharyngeal

#LocallyAdvancedOralandOropharyng#Antibody#Phase2#monoclonal-antibody#Lepu
Trials 11Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 1

anti-GPC3 CAR-T (anti-GPC3 CAR-T)

Advanced Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 11Status Recruiting
CGTLimited DatastaleAsclepius Technology Company Gr…Phase 1

Anti-BCMA CAR-NK Cells (Anti-BCMA CAR-NK Cells)

Multiple Myeloma, Refractory · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 10Status Active
CGTLimited DatastaleTakedaPhase 2

Anti-CD19 CAR T Cells Preparation (Anti-CD19 CAR T Cells Preparation)

Hematologic Malignancies · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 10Status Recruiting
CGTLimited DatastaleShenzhen Celconta Life Science …Phase 1

Claudin18.2-targeted CAR-T Cells (Claudin18.2-targeted CAR-T Cells)

Colorectal Neoplasia · Colorectal Neoplasia

#ColorectalNeoplasia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 10Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Dual-target CAR-NK cell product (Dual-target CAR-NK cell product)

Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 10Status Recruiting

10 / 55 pages

← PreviousNext →